Literature DB >> 24709846

Glomerular disease. Antiproteinuric efficacy of A. manihot superior to losartan.

Ellen F Carney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24709846     DOI： 10.1038/nrneph.2014.63

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  1 in total

1.  Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.

Authors:  Li Zhang; Ping Li; Chang-ying Xing; Jiu-yang Zhao; Ya-ni He; Jian-qin Wang; Xiong-fei Wu; Zhang-suo Liu; Ai-ping Zhang; Hong-li Lin; Xiao-qiang Ding; Ai-ping Yin; Fa-huan Yuan; Ping Fu; Li Hao; Li-ning Miao; Ru-juan Xie; Rong Wang; Chun-hua Zhou; Guang-ju Guan; Zhao Hu; Shan Lin; Ming Chang; Miao Zhang; Li-qun He; Chang-lin Mei; Li Wang; Xiangmei Chen
Journal:  Am J Kidney Dis       Date:  2014-03-14       Impact factor: 8.860
  1 in total
  6 in total

1.  Integrated Network Pharmacology Analysis and Pharmacological Evaluation to Explore the Active Components and Mechanism of Abelmoschus manihot (L.) Medik. on Renal Fibrosis.

Authors:  Lifei Gu; Fang Hong; Kaikai Fan; Lei Zhao; Chunlei Zhang; Boyang Yu; Chengzhi Chai
Journal:  Drug Des Devel Ther       Date:  2020-10-01       Impact factor: 4.162

2.  Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.

Authors:  Ping Li; Yi-Zhi Chen; Hong-Li Lin; Zhao-Hui Ni; Yong-Li Zhan; Rong Wang; Hong-Tao Yang; Jing-Ai Fang; Nian-Song Wang; Wen-Ge Li; Xue-Feng Sun; Xiang-Mei Chen
Journal:  Trials       Date:  2017-04-11       Impact factor: 2.279

3.  Huangkui Capsule Ameliorates Renal Fibrosis in a Unilateral Ureteral Obstruction Mouse Model Through TRPC6 Dependent Signaling Pathways.

Authors:  Li-Fei Gu; Hai-Tao Ge; Lei Zhao; Yu-Jing Wang; Fan Zhang; Hai-Tao Tang; Zheng-Yu Cao; Bo-Yang Yu; Cheng-Zhi Chai
Journal:  Front Pharmacol       Date:  2020-07-03       Impact factor: 5.810

4.  Total extract of Abelmoschus manihot L. alleviates uric acid-induced renal tubular epithelial injury via inhibition of caspase-8/caspase-3/NLRP3/GSDME signaling.

Authors:  Zhihui Ding; Jing Zhao; Xufang Wang; Wei Li; Chong Chen; Chen Yong; Yiye Zhu; Fang Tian; Li Liu; Manshu Yu; Enchao Zhou; Liubao Gu; Chunlei Yao; Kun Gao
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

Review 5.  The Effectiveness and Safety of Abelmoschus manihot in Treating IgA Nephropathy: A Systematic Review and Meta-Analysis.

Authors:  Qi Jia; Jing Guo; Yuzi Cai; Weijun Huang; Zebing Zhu; Chenhui Xia; Keting Guo; Hongcai Shang; Yuning Liu; Weijing Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-05       Impact factor: 2.650

Review 6.  Molecular Mechanistic Pathways Targeted by Natural Antioxidants in the Prevention and Treatment of Chronic Kidney Disease.

Authors:  Mohamed Mohany; Mohammed M Ahmed; Salim S Al-Rejaie
Journal:  Antioxidants (Basel)       Date:  2021-12-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.